New immunotherapy combo aims to stop colorectal cancer relapse
NCT ID NCT07058012
First seen May 20, 2026 · Last updated Jun 04, 2026 · Updated 2 times
Summary
This study tests whether immunotherapy drugs (cemiplimab alone or with fianlimab) can clear leftover cancer DNA in the blood of colorectal cancer patients after surgery and chemotherapy. About 79 adults with stage II/III colon or rectal cancer who still have cancer DNA markers will receive these treatments. The goal is to see if the drugs can make the cancer DNA disappear and keep it gone for 12 months, potentially delaying or preventing the cancer from returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
RECRUITINGGainesville, Florida, 32611, United States
Conditions
Explore the condition pages connected to this study.